Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for <font color="red">advanced_3</font> <font color="red">nasopharyngeal_3</font> <font color="red">carcinoma_3</font> <font color="red">:_3</font> positive effect on overall and progression - free survival . 
<br>
<br> <font color="red">PURPOSE_1</font> <font color="red">Nasopharyngeal_2</font> <font color="red">carcinoma_2</font> <font color="red">(_2</font> <font color="red">NPC_2</font> <font color="red">)_2</font> <font color="red">is_2</font> <font color="red">a_2</font> <font color="red">radiosensitive_2</font> <font color="red">and_2</font> <font color="red">chemosensitive_2</font> <font color="red">tumor_2</font> <font color="red">._2</font> This randomized phase III trial compared concurrent chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone in <font color="red">patients_4</font> <font color="red">with_4</font> <font color="red">advanced_4</font> <font color="red">NPC_4</font> <font color="red">._4</font> 
<br> <font color="red">PATIENTS_1</font> <font color="red">AND_1</font> <font color="red">METHODS_1</font> <font color="red">From_3</font> <font color="red">December_4</font> <font color="red">1993_4</font> <font color="red">to_4</font> <font color="red">April_4</font> <font color="red">1999_4</font> <font color="red">,_4</font> <font color="red">284_7</font> <font color="red">patients_7</font> <font color="red">with_7</font> <font color="red">1992_7</font> <font color="red">American_7</font> <font color="red">Joint_7</font> <font color="red">Committee_7</font> <font color="red">on_7</font> <font color="red">Cancer_7</font> <font color="red">stage_7</font> <font color="red">III_7</font> <font color="red">to_7</font> <font color="red">IV_7</font> <font color="red">(_6</font> <font color="red">M0_6</font> <font color="red">)_6</font> <font color="red">NPC_6</font> <font color="red">were_2</font> <font color="red">randomly_2</font> <font color="red">allocated_2</font> <font color="red">into_1</font> <font color="red">two_1</font> <font color="red">arms_1</font> <font color="red">._1</font> Similar dosage and fractionation of RT was administered in <font color="red">both_1</font> <font color="red">arms_1</font> <font color="red">._1</font> The <font color="red">investigational_1</font> <font color="red">arm_1</font> received two cycles of concurrent chemotherapy with cisplatin 20 mg / m(2)/d plus fluorouracil 400 mg / m(2)/d by 96-hour continuous infusion during the weeks 1 and 5 of RT . Survival analysis was estimated by the Kaplan - Meier method and compared by the log - rank test . 
<br> <font color="red">RESULTS_1</font> <font color="red">Baseline_1</font> <font color="red">patient_2</font> <font color="red">characteristics_1</font> <font color="red">were_1</font> <font color="red">comparable_1</font> <font color="red">in_1</font> <font color="red">both_2</font> <font color="red">arms_2</font> <font color="red">._2</font> After a median follow - up of 65 months , 26.2% ( 37 of 141 ) and 46.2% ( 66 of 143 ) of <font color="red">patients_1</font> developed tumor relapse in the <font color="red">CCRT_1</font> <font color="red">and_1</font> <font color="red">RT_1</font> <font color="red">-_1</font> <font color="red">alone_1</font> <font color="red">groups_1</font> <font color="red">,_1</font> respectively . The 5-year overall survival rates were 72.3% for the <font color="red">CCRT_1</font> <font color="red">arm_1</font> and 54.2% for the <font color="red">RT_1</font> <font color="red">-_1</font> <font color="red">only_1</font> <font color="red">arm_1</font> ( P = .0022 ) . The 5-year progression - free survival rates were 71.6% for the CCRT group compared with 53.0% for the RT - only group ( P = .0012 ) . Although significantly more toxicity was noted in the <font color="red">CCRT_1</font> <font color="red">arm_1</font> <font color="red">,_1</font> including leukopenia and emesis , compliance with the combined treatment was good . The second cycle of concurrent chemotherapy was refused by <font color="red">nine_1</font> <font color="red">patients_1</font> and was delayed for > or = 1 week for another <font color="red">nine_1</font> <font color="red">patients_1</font> <font color="red">._1</font> There were no treatment - related deaths in <font color="red">either_1</font> <font color="red">arm_1</font> <font color="red">._1</font> 
<br> <font color="red">CONCLUSION_1</font> <font color="red">We_1</font> <font color="red">conclude_1</font> <font color="red">that_1</font> <font color="red">CCRT_1</font> <font color="red">is_1</font> <font color="red">superior_1</font> <font color="red">to_1</font> <font color="red">RT_1</font> <font color="red">alone_1</font> <font color="red">for_1</font> <font color="red">patients_3</font> <font color="red">with_3</font> <font color="red">advanced_3</font> <font color="red">NPC_3</font> <font color="red">in_1</font> <font color="red">endemic_1</font> <font color="red">areas_1</font> <font color="red">._1</font>